

# Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	4.4	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	9	2.4	373.0	(170.2-708.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	5	2.8	177.6	(57.2-414.5)
Female	22	19.0	115.9	(72.6-175.5)	Female	3	1.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.8	nc	(nc-nc)
Male	6	6.3	94.7	(34.6-206.2)	<b><u>Ovary</u></b>				
Female	5	4.7	107.1	(34.5-250.0)	Female	0	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	26	21.1	123.1	(80.4-180.3)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.1	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	3.4	149.0	(48.0-347.8)
Male	4	1.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.1	nc	(nc-nc)	Female	5	4.3	115.4	(37.2-269.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	76	69.1	109.9	(86.6-137.6)
Female	0	0.4	nc	(nc-nc)	Female	68	58.0	117.2	(91.0-148.6)
<b><u>Lung and Bronchus</u></b>									
Male	3	8.8	nc	(nc-nc)					
Female	3	7.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	14.3	118.9	(69.2-190.3)	Male	9	8.6	104.6	(47.8-198.7)
Female	4	4.8	nc	(nc-nc)	Female	11	6.3	173.5	(86.5-310.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	6	7.6	78.8	(28.8-171.5)
Female	49	46.9	104.6	(77.3-138.2)	Female	3	6.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	2	5.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.3	nc	(nc-nc)
Male	10	17.7	56.4	(27.0-103.8)	<b><u>Ovary</u></b>				
Female	13	15.8	82.4	(43.8-140.9)	Female	5	4.5	110.1	(35.5-257.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	3.6	194.8	(78.0-401.3)	Male	6	4.4	135.9	(49.6-295.8)
Female	0	0.9	nc	(nc-nc)	Female	6	4.2	142.3	(52.0-309.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	56	50.1	111.9	(84.5-145.3)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.4	nc	(nc-nc)
Male	10	7.0	142.9	(68.4-262.8)	Female	0	1.7	nc	(nc-nc)
Female	7	3.9	177.7	(71.2-366.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.6	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	7.6	118.3	(54.0-224.6)
Male	6	4.9	123.1	(44.9-267.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.4	147.8	(47.6-344.8)	Female	11	10.4	105.4	(52.6-188.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	193	182.9	105.5	(91.2-121.5)
Female	0	1.2	nc	(nc-nc)	Female	175	164.0	106.7	(91.5-123.7)
<b><u>Lung and Bronchus</u></b>									
Male	27	25.9	104.3	(68.7-151.8)					
Female	29	24.0	120.7	(80.8-173.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	1.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	10	5.4	185.4	(88.7-340.9)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	4	1.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.7	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	5.9	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.9	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	19	19.7	96.5	(58.1-150.7)
Female	0	0.1	nc	(nc-nc)	Female	22	18.2	121.1	(75.9-183.4)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.6	nc	(nc-nc)					
Female	4	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	9.2	98.1	(44.8-186.3)	Male	6	6.8	88.2	(32.2-192.0)
Female	2	3.2	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.9	102.0	(37.3-222.1)
Female	41	39.0	105.1	(75.4-142.6)	Female	6	4.5	134.6	(49.2-293.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	6	4.4	136.8	(50.0-297.8)
<b><u>Colon / Rectum</u></b>					Female	3	1.8	nc	(nc-nc)
Male	11	12.7	86.9	(43.3-155.4)	<b><u>Ovary</u></b>				
Female	10	11.7	85.6	(41.0-157.4)	Female	7	3.6	192.2	(77.0-396.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	2.9	204.7	(74.8-445.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	33	37.0	89.2	(61.4-125.2)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.3	nc	(nc-nc)
Male	1	5.6	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.9	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	7.9	113.8	(51.9-216.1)
Male	5	3.7	135.2	(43.6-315.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.7	nc	(nc-nc)	Female	10	8.3	121.2	(58.0-222.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	125	134.3	93.1	(77.5-110.9)
Female	2	0.9	nc	(nc-nc)	Female	149	128.6	115.9	(98.0-136.0)
<b><u>Lung and Bronchus</u></b>									
Male	18	17.0	106.1	(62.8-167.6)					
Female	22	15.5	141.9	(88.9-214.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chatham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	17.5	103.1	(61.1-162.9)	Male	17	8.9	191.6	(111.6-306.8)
Female	12	6.2	194.2	(100.2-339.3)	Female	11	5.9	186.2	(92.8-333.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	13	8.0	162.6	(86.5-278.1)
Female	65	46.1	140.9	(108.7-179.6)	Female	4	7.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	7	4.8	145.4	(58.3-299.6)
<b><u>Colon / Rectum</u></b>					Female	2	2.5	nc	(nc-nc)
Male	19	20.2	94.1	(56.6-147.0)	<b><u>Ovary</u></b>				
Female	12	20.6	58.2	(30.1-101.8)	Female	7	4.8	147.0	(58.9-302.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	3.9	128.5	(41.4-299.9)	Male	2	5.1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	3	5.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	71	53.8	132.0	(103.1-166.4)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	4.0	nc	(nc-nc)
Male	8	7.1	113.4	(48.8-223.5)	Female	2	2.4	nc	(nc-nc)
Female	6	4.2	141.5	(51.7-308.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	5.2	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	3.8	157.7	(57.6-343.3)	Female	5	10.5	47.6	(15.3-111.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	208	199.7	104.1	(90.5-119.3)
Female	1	1.4	nc	(nc-nc)	Female	183	178.8	102.3	(88.0-118.3)
<b><u>Lung and Bronchus</u></b>									
Male	18	30.3	59.4	(35.2-93.8)					
Female	27	28.7	94.2	(62.1-137.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	35.0	94.3	(64.9-132.4)	Male	29	23.4	124.2	(83.1-178.3)
Female	19	14.1	135.1	(81.3-211.0)	Female	18	19.3	93.4	(55.3-147.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	7.3	82.5	(30.1-179.6)	Male	4	5.8	nc	(nc-nc)
Female	2	6.1	nc	(nc-nc)	Female	7	4.7	150.3	(60.2-309.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	18	20.1	89.7	(53.1-141.7)
Female	191	144.8	131.9	(113.9-152.0)	Female	20	18.0	110.9	(67.7-171.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	5.9	101.6	(37.1-221.0)	Male	17	14.8	115.1	(67.0-184.3)
<b><u>Colon / Rectum</u></b>					Female	5	6.9	72.0	(23.2-168.0)
Male	51	45.6	111.9	(83.3-147.1)	<b><u>Ovary</u></b>				
Female	55	47.2	116.5	(87.7-151.6)	Female	11	14.0	78.8	(39.3-141.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	9.8	123.0	(63.5-215.0)	Male	12	11.3	106.4	(54.9-185.9)
Female	6	2.7	220.3	(80.5-479.6)	Female	10	12.5	80.1	(38.4-147.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	3.1	nc	(nc-nc)	Male	169	140.9	119.9	(102.5-139.4)
Female	4	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	8.5	106.1	(48.4-201.5)
Male	19	19.4	98.0	(59.0-153.0)	Female	7	5.3	132.7	(53.2-273.4)
Female	11	11.7	93.7	(46.7-167.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	4.9	nc	(nc-nc)
Male	3	5.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	13	7.4	176.4	(93.8-301.6)
<b><u>Leukemia</u></b>					Female	19	23.7	80.3	(48.3-125.4)
Male	19	12.6	151.4	(91.1-236.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	19	10.0	189.4	(114.0-295.7)	Female	42	33.1	126.9	(91.4-171.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	10.0	119.8	(61.9-209.4)	Male	543	488.0	111.3	(102.1-121.0)
Female	4	3.5	nc	(nc-nc)	Female	578	496.3	116.5	(107.2-126.4)
<b><u>Lung and Bronchus</u></b>									
Male	66	65.8	100.3	(77.5-127.6)					
Female	70	69.7	100.5	(78.3-126.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelsea

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	29.2	68.4	(41.8-105.7)	Male	8	19.1	41.9	(18.0-82.5)
Female	11	10.3	107.1	(53.4-191.6)	Female	3	15.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	6.4	155.7	(74.5-286.4)	Male	4	4.6	nc	(nc-nc)
Female	1	5.1	nc	(nc-nc)	Female	6	3.3	181.3	(66.2-394.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	17	16.8	101.2	(58.9-162.0)
Female	80	100.1	79.9	(63.3-99.4)	Female	14	13.3	105.3	(57.5-176.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	4.9	164.7	(70.9-324.5)	Male	11	10.9	101.2	(50.4-181.0)
<b><u>Colon / Rectum</u></b>					Female	6	5.0	120.1	(43.8-261.3)
Male	34	37.0	92.0	(63.7-128.6)	<b><u>Ovary</u></b>				
Female	43	35.1	122.4	(88.6-164.9)	Female	7	9.9	71.0	(28.4-146.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	7.4	108.6	(46.8-214.0)	Male	10	9.1	110.4	(52.8-203.0)
Female	3	2.0	nc	(nc-nc)	Female	10	9.2	109.1	(52.2-200.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	78	102.4	76.2	(60.2-95.1)
Female	1	2.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	7.0	156.3	(77.9-279.7)
Male	21	14.9	140.5	(86.9-214.8)	Female	11	4.0	272.3	(135.7-487.3)
Female	8	8.3	96.0	(41.3-189.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	6.0	nc	(nc-nc)
Male	2	4.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	1.1	nc	(nc-nc)	Male	6	6.2	97.1	(35.5-211.4)
<b><u>Leukemia</u></b>					Female	27	19.5	138.4	(91.2-201.4)
Male	12	11.1	107.7	(55.6-188.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	8.2	61.2	(19.7-142.8)	Female	14	21.7	64.5	(35.2-108.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	7.4	148.8	(74.2-266.3)	Male	359	387.7	92.6	(83.3-102.7)
Female	6	2.6	234.1	(85.5-509.6)	Female	349	359.9	97.0	(87.1-107.7)
<b><u>Lung and Bronchus</u></b>									
Male	72	52.4	137.3	(107.4-172.9)					
Female	52	48.9	106.4	(79.5-139.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	4.4	227.8	(109.1-419.0)	Male	6	2.8	216.2	(79.0-470.7)
Female	3	1.3	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	19	13.6	139.2	(83.8-217.4)	Female	2	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.7	nc	(nc-nc)
Male	6	5.6	106.6	(38.9-232.0)	<b><u>Ovary</u></b>				
Female	2	4.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	23	17.0	135.0	(85.5-202.6)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.3	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.9	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	78	59.2	131.9	(104.2-164.6)
Female	0	0.3	nc	(nc-nc)	Female	45	46.2	97.3	(71.0-130.2)
<b><u>Lung and Bronchus</u></b>									
Male	10	8.1	122.7	(58.7-225.7)					
Female	4	6.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	11	4.9	223.5	(111.4-399.9)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.5	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.9	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	11	19.3	56.9	(28.4-101.8)
Female	0	0.1	nc	(nc-nc)	Female	21	16.4	128.3	(79.4-196.2)
<b><u>Lung and Bronchus</u></b>									
Male	0	2.6	nc	(nc-nc)					
Female	3	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	5	4.8	104.4	(33.6-243.5)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	5.2	115.1	(42.0-250.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.9	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	18	17.9	100.3	(59.4-158.5)
Female	0	0.1	nc	(nc-nc)	Female	14	15.4	90.7	(49.5-152.1)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.4	nc	(nc-nc)					
Female	0	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	67	68.2	98.3	(76.2-124.8)	Male	29	40.9	70.9	(47.5-101.9)
Female	21	27.0	77.7	(48.1-118.8)	Female	22	33.1	66.5	(41.7-100.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	12.3	81.4	(39.0-149.8)	Male	10	10.6	94.7	(45.4-174.2)
Female	13	10.6	122.7	(65.3-209.8)	Female	7	8.8	79.6	(31.9-164.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	40	36.0	111.0	(79.3-151.2)
Female	241	242.4	99.4	(87.3-112.8)	Female	33	33.4	98.7	(67.9-138.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	9.3	96.5	(44.0-183.2)	Male	23	24.2	95.1	(60.2-142.6)
<b><u>Colon / Rectum</u></b>					Female	15	12.2	122.9	(68.8-202.8)
Male	56	84.0	66.6	(50.3-86.5)	<b><u>Ovary</u></b>				
Female	90	89.9	100.2	(80.5-123.1)	Female	20	24.1	83.0	(50.7-128.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	18	17.2	104.6	(62.0-165.4)	Male	16	21.1	75.9	(43.4-123.3)
Female	2	5.3	nc	(nc-nc)	Female	24	24.1	99.7	(63.9-148.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	5.4	nc	(nc-nc)	Male	212	241.2	87.9	(76.4-100.5)
Female	4	4.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	27	16.1	168.1	(110.8-244.6)
Male	19	33.2	57.3	(34.5-89.4)	Female	14	10.2	137.8	(75.3-231.3)
Female	18	20.9	86.0	(50.9-135.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	8.0	124.9	(59.8-229.6)
Male	8	9.8	81.6	(35.1-160.8)	<b><u>Thyroid</u></b>				
Female	3	2.8	nc	(nc-nc)	Male	4	11.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	27	37.1	72.7	(47.9-105.8)
Male	19	23.0	82.7	(49.8-129.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	18.4	81.4	(45.5-134.3)	Female	62	54.7	113.3	(86.9-145.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	16	16.9	94.5	(54.0-153.5)	Male	809	873.1	92.7	(86.4-99.3)
Female	10	6.5	154.2	(73.8-283.7)	Female	861	879.7	97.9	(91.4-104.6)
<b><u>Lung and Bronchus</u></b>									
Male	154	123.5	124.7	(105.7-146.0)					
Female	153	131.3	116.5	(98.8-136.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	5	4.8	103.3	(33.3-241.0)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	4	2.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	14	6.1	231.1	(126.3-387.8)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.7	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	26	21.1	123.4	(80.6-180.8)
Female	0	0.1	nc	(nc-nc)	Female	15	16.7	89.9	(50.3-148.2)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.0	nc	(nc-nc)					
Female	3	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	2.1	282.2	(103.1-614.3)	Male	0	1.4	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	2	7.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.4	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	2.5	242.8	(88.6-528.4)	Female	1	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	8.8	68.2	(24.9-148.5)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.2	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	31	29.4	105.6	(71.8-149.9)
Female	0	0.2	nc	(nc-nc)	Female	24	25.8	93.1	(59.6-138.5)
<b><u>Lung and Bronchus</u></b>									
Male	7	4.1	171.9	(68.9-354.1)					
Female	8	3.7	213.9	(92.1-421.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	14.5	68.8	(32.9-126.5)	Male	10	9.3	107.7	(51.5-198.0)
Female	9	6.2	145.9	(66.6-277.1)	Female	1	8.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	4	8.1	nc	(nc-nc)
Female	48	57.1	84.1	(62.0-111.5)	Female	7	7.7	90.6	(36.3-186.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.4	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	2.9	nc	(nc-nc)
Male	22	18.4	119.9	(75.1-181.5)	<b><u>Ovary</u></b>				
Female	26	20.9	124.4	(81.3-182.3)	Female	2	5.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.8	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	6	5.5	108.7	(39.7-236.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	37	53.1	69.6	(49.0-96.0)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	3.5	200.9	(80.5-414.0)
Male	10	7.5	133.2	(63.8-245.0)	Female	3	2.4	nc	(nc-nc)
Female	8	4.8	166.2	(71.5-327.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.2	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	9.4	96.0	(43.8-182.2)
Male	1	5.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	4.3	nc	(nc-nc)	Female	13	12.6	103.0	(54.8-176.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	3.8	131.6	(42.4-307.0)	Male	167	193.0	86.5	(73.9-100.7)
Female	2	1.5	nc	(nc-nc)	Female	194	205.3	94.5	(81.6-108.7)
<b><u>Lung and Bronchus</u></b>									
Male	25	26.6	94.1	(60.9-139.0)					
Female	31	29.5	104.9	(71.3-149.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	8.7	80.4	(32.2-165.6)	Male	14	5.5	254.1	(138.8-426.4)
Female	3	3.3	nc	(nc-nc)	Female	11	4.2	260.8	(130.0-466.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.7	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
Female	27	32.5	83.0	(54.7-120.7)	Female	2	4.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.6	nc	(nc-nc)
Male	15	11.2	134.2	(75.1-221.4)	<b><u>Ovary</u></b>				
Female	14	10.9	128.6	(70.3-215.8)	Female	6	3.1	191.7	(70.0-417.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	46	33.6	136.7	(100.1-182.4)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.1	nc	(nc-nc)
Male	5	4.6	108.7	(35.0-253.6)	Female	0	1.2	nc	(nc-nc)
Female	5	2.7	187.1	(60.3-436.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	5.0	119.0	(43.5-259.1)
Male	4	3.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.3	nc	(nc-nc)	Female	11	7.4	149.6	(74.6-267.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	143	117.3	121.9	(102.8-143.6)
Female	0	0.8	nc	(nc-nc)	Female	119	112.1	106.1	(87.9-127.0)
<b><u>Lung and Bronchus</u></b>									
Male	17	16.1	105.3	(61.3-168.6)					
Female	16	16.1	99.7	(56.9-161.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	8	6.8	118.4	(51.0-233.3)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	8.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.2	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.5	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	14	29.9	46.8	(25.5-78.5)
Female	0	0.2	nc	(nc-nc)	Female	24	22.5	106.6	(68.3-158.6)
<b><u>Lung and Bronchus</u></b>									
Male	2	4.1	nc	(nc-nc)					
Female	3	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	23.2	64.7	(36.2-106.7)	Male	31	14.3	216.4	(147.0-307.2)
Female	8	8.0	100.3	(43.2-197.7)	Female	15	9.9	151.8	(84.9-250.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	4.2	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	9	12.5	72.2	(32.9-137.1)
Female	107	77.0	139.0	(113.9-168.0)	Female	8	9.9	80.7	(34.7-158.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.9	nc	(nc-nc)	Male	6	8.7	68.7	(25.1-149.5)
<b><u>Colon / Rectum</u></b>					Female	2	3.7	nc	(nc-nc)
Male	22	29.3	75.2	(47.1-113.8)	<b><u>Ovary</u></b>				
Female	30	27.1	110.8	(74.8-158.2)	Female	12	7.5	160.7	(83.0-280.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	6.0	nc	(nc-nc)	Male	2	7.3	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	5	7.2	69.9	(22.5-163.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	104	85.3	122.0	(99.7-147.8)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	5.5	nc	(nc-nc)
Male	9	11.7	76.7	(35.0-145.6)	Female	1	3.1	nc	(nc-nc)
Female	8	6.3	126.6	(54.5-249.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.5	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	11.3	62.0	(24.8-127.7)
Male	17	7.8	216.7	(126.2-347.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	5.5	127.3	(51.0-262.2)	Female	16	17.4	92.1	(52.6-149.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	6.0	nc	(nc-nc)	Male	262	303.6	86.3	(76.2-97.4)
Female	1	1.9	nc	(nc-nc)	Female	282	268.2	105.1	(93.2-118.1)
<b><u>Lung and Bronchus</u></b>									
Male	23	42.4	54.3	(34.4-81.5)					
Female	20	38.4	52.0	(31.8-80.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	7	7.5	93.5	(37.5-192.7)	Female	1	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	13	8.0	162.7	(86.6-278.3)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	28	27.2	102.8	(68.3-148.5)
Female	0	0.2	nc	(nc-nc)	Female	17	23.9	71.2	(41.5-114.0)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.5	nc	(nc-nc)					
Female	0	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	Female	3	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	6	4.0	151.3	(55.2-329.3)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.7	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	13	13.7	94.8	(50.4-162.2)
Female	0	0.1	nc	(nc-nc)	Female	19	12.9	146.8	(88.3-229.3)
<b><u>Lung and Bronchus</u></b>									
Male	3	1.8	nc	(nc-nc)					
Female	3	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	8.1	148.5	(76.6-259.4)	Male	6	5.0	120.5	(44.0-262.2)
Female	5	3.4	147.5	(47.5-344.3)	Female	6	4.1	144.6	(52.8-314.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	23	31.2	73.6	(46.7-110.5)	Female	4	4.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.6	nc	(nc-nc)
Male	15	10.2	147.4	(82.5-243.2)	<b><u>Ovary</u></b>				
Female	23	11.4	201.5	(127.7-302.4)	Female	3	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.1	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	23	29.8	77.3	(49.0-115.9)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	6	4.1	146.5	(53.5-318.8)	Female	2	1.3	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.9	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.7	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.3	nc	(nc-nc)	Female	10	7.0	143.0	(68.4-262.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	2.1	nc	(nc-nc)	Male	101	106.1	95.2	(77.6-115.7)
Female	2	0.8	nc	(nc-nc)	Female	119	111.5	106.7	(88.4-127.7)
<b><u>Lung and Bronchus</u></b>									
Male	13	14.9	87.5	(46.6-149.7)					
Female	14	16.4	85.5	(46.7-143.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	32.9	118.5	(84.2-162.0)	Male	30	20.1	149.6	(100.9-213.6)
Female	11	13.1	83.7	(41.7-149.8)	Female	21	16.2	129.6	(80.2-198.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.9	84.4	(27.2-197.1)	Male	4	5.2	nc	(nc-nc)
Female	8	5.1	155.4	(66.9-306.1)	Female	2	4.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	19	17.5	108.7	(65.4-169.7)
Female	134	121.5	110.3	(92.4-130.6)	Female	24	16.3	147.6	(94.5-219.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.7	nc	(nc-nc)	Male	12	12.1	99.0	(51.1-173.0)
<b><u>Colon / Rectum</u></b>					Female	9	6.0	149.5	(68.2-283.7)
Male	45	41.1	109.4	(79.8-146.4)	<b><u>Ovary</u></b>				
Female	52	44.2	117.6	(87.8-154.2)	Female	12	11.9	100.6	(51.9-175.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	8.5	82.7	(33.1-170.5)	Male	16	10.3	155.9	(89.1-253.3)
Female	5	2.6	195.7	(63.1-456.8)	Female	22	11.8	187.0	(117.2-283.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	145	120.5	120.3	(101.5-141.6)
Female	5	2.0	247.1	(79.6-576.7)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	7.8	115.2	(52.6-218.7)
Male	17	16.4	103.7	(60.4-166.0)	Female	3	5.0	nc	(nc-nc)
Female	12	10.2	117.6	(60.7-205.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	3.5	256.9	(117.2-487.8)
Male	2	4.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	13	18.4	70.5	(37.5-120.6)
Male	15	11.1	135.4	(75.7-223.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	9.0	133.3	(68.8-232.8)	Female	39	27.3	143.1	(101.7-195.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	8.4	83.2	(33.3-171.5)	Male	490	428.1	114.5	(104.5-125.1)
Female	4	3.2	nc	(nc-nc)	Female	511	433.3	117.9	(107.9-128.6)
<b><u>Lung and Bronchus</u></b>									
Male	61	60.1	101.4	(77.6-130.3)					
Female	71	63.1	112.4	(87.8-141.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dartmouth

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	43	37.0	116.2	(84.1-156.6)	Male	10	23.0	43.5	(20.8-79.9)
Female	21	13.9	150.8	(93.3-230.6)	Female	16	17.8	90.1	(51.4-146.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	6.9	115.3	(49.7-227.2)	Male	6	5.8	102.7	(37.5-223.5)
Female	5	5.6	89.5	(28.8-208.7)	Female	2	4.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	21	20.2	104.1	(64.4-159.1)
Female	133	130.7	101.8	(85.2-120.6)	Female	20	17.4	114.7	(70.0-177.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	5.1	nc	(nc-nc)	Male	12	13.9	86.1	(44.4-150.4)
<b><u>Colon / Rectum</u></b>					Female	3	6.5	nc	(nc-nc)
Male	53	46.6	113.8	(85.2-148.8)	<b><u>Ovary</u></b>				
Female	49	46.9	104.4	(77.2-138.0)	Female	13	12.9	100.8	(53.6-172.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	9.6	135.8	(72.2-232.2)	Male	11	11.6	95.0	(47.4-170.0)
Female	2	2.7	nc	(nc-nc)	Female	9	12.5	72.3	(33.0-137.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.2	nc	(nc-nc)	Male	182	135.2	134.7	(115.8-155.7)
Female	2	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	16	8.8	181.6	(103.7-294.9)
Male	24	18.7	128.3	(82.2-190.9)	Female	3	5.3	nc	(nc-nc)
Female	9	10.9	82.2	(37.5-156.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	4.9	nc	(nc-nc)
Male	7	5.5	127.7	(51.1-263.0)	<b><u>Thyroid</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	14	6.8	205.0	(112.0-343.9)
<b><u>Leukemia</u></b>					Female	18	20.5	87.7	(52.0-138.6)
Male	15	12.8	117.5	(65.7-193.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	9.6	73.0	(29.2-150.4)	Female	40	29.4	136.3	(97.3-185.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	9.6	52.0	(16.8-121.3)	Male	556	486.0	114.4	(105.1-124.3)
Female	3	3.4	nc	(nc-nc)	Female	453	465.2	97.4	(88.6-106.8)
<b><u>Lung and Bronchus</u></b>									
Male	81	67.3	120.3	(95.5-149.6)					
Female	55	67.4	81.6	(61.5-106.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dedham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	30.6	98.1	(66.2-140.1)	Male	20	18.6	107.5	(65.7-166.1)
Female	15	11.4	132.0	(73.8-217.7)	Female	21	14.2	147.9	(91.5-226.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	5.5	180.4	(86.3-331.7)	Male	4	4.8	nc	(nc-nc)
Female	5	4.5	110.2	(35.5-257.2)	Female	2	3.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	19	16.2	117.0	(70.4-182.6)
Female	110	106.9	102.9	(84.6-124.1)	Female	13	14.1	92.0	(49.0-157.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.1	nc	(nc-nc)	Male	11	11.1	98.9	(49.3-177.0)
<b><u>Colon / Rectum</u></b>					Female	4	5.3	nc	(nc-nc)
Male	42	38.0	110.6	(79.7-149.5)	<b><u>Ovary</u></b>				
Female	36	37.8	95.3	(66.7-132.0)	Female	6	10.5	57.2	(20.9-124.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	7.8	102.6	(44.2-202.2)	Male	10	9.5	105.3	(50.4-193.6)
Female	4	2.2	nc	(nc-nc)	Female	7	10.1	69.3	(27.7-142.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	110	110.3	99.7	(82.0-120.2)
Female	2	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	7.2	96.7	(38.7-199.3)
Male	10	15.1	66.1	(31.6-121.5)	Female	6	4.3	140.5	(51.3-305.9)
Female	15	9.0	166.3	(93.0-274.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	3.5	nc	(nc-nc)
Male	5	4.5	112.1	(36.1-261.7)	<b><u>Thyroid</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	11	5.4	205.5	(102.5-367.8)
<b><u>Leukemia</u></b>					Female	27	16.4	164.6	(108.5-239.5)
Male	12	10.3	116.2	(60.0-203.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	7.8	115.2	(52.6-218.6)	Female	16	24.3	65.8	(37.6-106.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	7.7	90.6	(36.3-186.6)	Male	398	395.5	100.6	(91.0-111.0)
Female	1	2.7	nc	(nc-nc)	Female	401	379.0	105.8	(95.7-116.7)
<b><u>Lung and Bronchus</u></b>									
Male	56	55.7	100.6	(76.0-130.6)					
Female	61	55.8	109.4	(83.7-140.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	5.8	121.2	(48.6-249.7)	Male	6	3.7	160.1	(58.5-348.5)
Female	3	2.0	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	4	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.2	153.9	(49.6-359.2)
Female	23	20.9	109.9	(69.6-164.9)	Female	3	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.0	nc	(nc-nc)
Male	8	7.5	107.0	(46.1-210.9)	<b><u>Ovary</u></b>				
Female	2	6.7	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	25	22.7	110.1	(71.2-162.5)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.4	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.4	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	6	4.8	125.3	(45.8-272.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	84	79.0	106.3	(84.8-131.6)
Female	0	0.5	nc	(nc-nc)	Female	67	70.8	94.6	(73.3-120.2)
<b><u>Lung and Bronchus</u></b>									
Male	8	10.7	75.1	(32.3-147.9)					
Female	5	9.8	51.0	(16.4-119.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	36	33.8	106.7	(74.7-147.7)	Male	37	17.8	207.5	(146.0-286.0)
Female	12	11.7	103.0	(53.1-179.9)	Female	27	12.3	219.5	(144.6-319.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
Female	5	3.9	126.6	(40.8-295.5)	Female	3	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	10	15.9	62.9	(30.1-115.7)
Female	126	95.9	131.3	(109.4-156.4)	Female	13	13.9	93.7	(49.9-160.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.2	nc	(nc-nc)	Male	21	10.0	210.5	(130.3-321.8)
<b><u>Colon / Rectum</u></b>					Female	3	4.9	nc	(nc-nc)
Male	45	39.4	114.1	(83.3-152.7)	<b><u>Ovary</u></b>				
Female	44	37.8	116.3	(84.5-156.1)	Female	11	9.7	113.9	(56.8-203.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	7.9	88.9	(35.6-183.1)	Male	8	10.1	79.3	(34.1-156.3)
Female	2	2.3	nc	(nc-nc)	Female	7	10.3	67.7	(27.1-139.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	148	110.5	133.9	(113.2-157.3)
Female	0	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	7.7	nc	(nc-nc)
Male	12	14.4	83.3	(43.0-145.5)	Female	2	4.3	nc	(nc-nc)
Female	13	8.7	149.9	(79.7-256.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.9	nc	(nc-nc)
Male	6	4.5	134.6	(49.2-293.0)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	12.3	64.9	(27.9-127.8)
Male	11	10.2	107.4	(53.6-192.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	16	7.3	218.3	(124.7-354.6)	Female	34	22.1	153.8	(106.5-214.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	7.3	96.0	(38.5-197.9)	Male	464	399.8	116.0	(105.7-127.1)
Female	1	2.7	nc	(nc-nc)	Female	430	356.9	120.5	(109.3-132.4)
<b><u>Lung and Bronchus</u></b>									
Male	54	60.0	89.9	(67.6-117.3)					
Female	63	57.0	110.5	(84.9-141.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	7.0	113.6	(48.9-223.9)	Male	3	4.6	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	27	26.3	102.5	(67.5-149.1)	Female	4	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.1	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.3	nc	(nc-nc)
Male	9	9.1	98.7	(45.0-187.3)	<b><u>Ovary</u></b>				
Female	4	8.7	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	0.6	nc	(nc-nc)	Male	20	27.0	74.0	(45.2-114.2)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	10	3.8	264.9	(126.8-487.2)	Female	4	1.0	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.0	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.5	111.4	(35.9-260.0)
Male	0	2.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	1.9	269.0	(86.7-627.8)	Female	4	5.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	88	96.0	91.7	(73.5-113.0)
Female	1	0.6	nc	(nc-nc)	Female	99	90.9	108.9	(88.5-132.6)
<b><u>Lung and Bronchus</u></b>									
Male	9	13.0	69.4	(31.7-131.7)					
Female	13	12.6	103.1	(54.8-176.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	5.4	183.5	(87.8-337.5)	Male	7	4.1	170.3	(68.2-350.9)
Female	1	1.9	nc	(nc-nc)	Female	5	3.5	144.2	(46.5-336.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	6	3.6	167.7	(61.2-365.0)
Female	25	23.3	107.5	(69.6-158.7)	Female	1	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.1	nc	(nc-nc)
Male	7	7.5	92.9	(37.2-191.4)	<b><u>Ovary</u></b>				
Female	5	6.8	73.4	(23.6-171.2)	Female	1	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	15	21.4	70.0	(39.1-115.4)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.4	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.3	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.9	103.0	(33.2-240.4)
Male	1	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.6	nc	(nc-nc)	Female	6	4.9	122.4	(44.7-266.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	78	79.9	97.7	(77.2-121.9)
Female	0	0.5	nc	(nc-nc)	Female	82	77.1	106.4	(84.6-132.1)
<b><u>Lung and Bronchus</u></b>									
Male	9	10.0	89.7	(40.9-170.3)					
Female	15	9.5	157.5	(88.1-259.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dover

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	6.1	nc	(nc-nc)	Male	7	4.1	171.0	(68.5-352.3)
Female	2	1.8	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	4	0.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.5	141.6	(45.6-330.5)
Female	26	22.3	116.3	(76.0-170.5)	Female	1	2.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.0	nc	(nc-nc)
Male	4	8.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	6.1	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	29	25.1	115.3	(77.2-165.6)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.5	nc	(nc-nc)
Male	4	3.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	3.8	210.9	(90.8-415.6)
Male	3	2.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	6	5.1	116.6	(42.6-253.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	75	86.3	86.9	(68.4-109.0)
Female	1	0.5	nc	(nc-nc)	Female	74	71.9	103.0	(80.8-129.3)
<b><u>Lung and Bronchus</u></b>									
Male	5	11.6	43.1	(13.9-100.7)					
Female	5	9.6	51.9	(16.7-121.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	27.0	144.2	(102.6-197.2)	Male	15	18.2	82.4	(46.1-135.9)
Female	19	10.1	187.7	(113.0-293.2)	Female	16	14.8	107.7	(61.5-175.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	5.9	152.7	(69.7-290.0)	Male	3	4.4	nc	(nc-nc)
Female	7	4.7	147.9	(59.2-304.7)	Female	2	3.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	20	15.8	126.9	(77.5-195.9)
Female	118	107.8	109.5	(90.6-131.1)	Female	17	13.2	128.7	(74.9-206.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	4.7	106.8	(34.4-249.3)	Male	18	11.3	159.5	(94.5-252.1)
<b><u>Colon / Rectum</u></b>					Female	7	5.1	136.9	(54.8-282.0)
Male	55	35.1	156.6	(117.9-203.8)	<b><u>Ovary</u></b>				
Female	31	33.4	92.8	(63.0-131.7)	Female	10	10.3	97.2	(46.5-178.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	7.5	120.7	(55.1-229.2)	Male	14	8.7	161.6	(88.3-271.1)
Female	2	2.0	nc	(nc-nc)	Female	11	8.9	123.7	(61.7-221.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	103	106.0	97.1	(79.3-117.8)
Female	2	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	6.6	91.5	(33.4-199.1)
Male	16	15.0	106.8	(61.0-173.5)	Female	7	3.7	190.1	(76.2-391.7)
Female	14	8.8	159.5	(87.1-267.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	4.5	111.1	(35.8-259.4)
Male	6	4.3	140.4	(51.3-305.6)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	4	5.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	24	19.1	125.8	(80.6-187.2)
Male	14	9.9	141.2	(77.1-236.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	7.5	173.8	(92.5-297.3)	Female	25	24.1	103.6	(67.0-152.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	7.7	116.8	(53.3-221.7)	Male	438	376.2	116.4	(105.8-127.9)
Female	1	2.5	nc	(nc-nc)	Female	441	367.3	120.1	(109.1-131.8)
<b><u>Lung and Bronchus</u></b>									
Male	61	50.8	120.0	(91.8-154.2)					
Female	75	51.7	145.0	(114.0-181.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	11.0	63.4	(25.4-130.7)	Male	2	7.1	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	Female	5	5.5	90.2	(29.1-210.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.2	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	6.2	80.3	(25.9-187.3)
Female	30	39.6	75.7	(51.1-108.1)	Female	3	5.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	6	4.4	136.9	(50.0-298.0)
<b><u>Colon / Rectum</u></b>					Female	1	1.9	nc	(nc-nc)
Male	19	14.1	134.4	(80.9-209.8)	<b><u>Ovary</u></b>				
Female	17	13.1	129.4	(75.3-207.1)	Female	4	3.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	35	41.5	84.4	(58.8-117.4)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.7	nc	(nc-nc)
Male	5	5.8	86.2	(27.8-201.2)	Female	0	1.5	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.7	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	6.9	130.7	(59.6-248.1)
Male	5	4.0	125.6	(40.5-293.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.8	nc	(nc-nc)	Female	5	8.8	57.1	(18.4-133.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.0	nc	(nc-nc)	Male	143	148.9	96.1	(81.0-113.2)
Female	1	1.0	nc	(nc-nc)	Female	120	137.4	87.4	(72.4-104.5)
<b><u>Lung and Bronchus</u></b>									
Male	25	20.3	123.4	(79.8-182.2)					
Female	18	19.2	93.8	(55.6-148.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	4	0.7	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	13	10.5	123.6	(65.8-211.4)	Female	2	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	10.7	74.9	(32.3-147.6)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.1	nc	(nc-nc)
Male	3	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	5	2.3	213.6	(68.8-498.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	30	36.5	82.2	(55.4-117.3)
Female	0	0.2	nc	(nc-nc)	Female	35	32.6	107.3	(74.7-149.2)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.6	nc	(nc-nc)					
Female	2	4.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	15.7	76.4	(39.4-133.5)	Male	31	10.5	295.8	(201.0-419.9)
Female	3	6.0	nc	(nc-nc)	Female	16	8.3	192.8	(110.1-313.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	9	9.0	99.5	(45.4-188.9)
Female	77	63.2	121.9	(96.2-152.4)	Female	10	7.7	129.7	(62.1-238.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.5	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	6	3.0	200.8	(73.3-437.0)
Male	14	20.8	67.4	(36.8-113.1)	<b><u>Ovary</u></b>				
Female	20	20.8	96.4	(58.8-148.8)	Female	10	6.0	165.5	(79.2-304.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	4.4	180.3	(77.6-355.3)	Male	1	5.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	3	5.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	96	63.9	150.3	(121.8-183.6)
Female	4	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.8	nc	(nc-nc)
Male	10	8.8	114.0	(54.6-209.6)	Female	2	2.3	nc	(nc-nc)
Female	4	5.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.8	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	6	3.2	185.6	(67.8-403.9)
<b><u>Leukemia</u></b>					Female	11	10.1	108.7	(54.2-194.4)
Male	7	5.7	123.3	(49.4-254.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.4	137.8	(50.3-300.0)	Female	11	14.1	77.8	(38.8-139.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.7	nc	(nc-nc)	Male	249	219.9	113.2	(99.6-128.2)
Female	4	1.5	nc	(nc-nc)	Female	244	213.7	114.2	(100.3-129.5)
<b><u>Lung and Bronchus</u></b>									
Male	17	29.3	57.9	(33.7-92.8)					
Female	29	28.9	100.3	(67.2-144.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	12.3	73.4	(33.5-139.3)	Male	9	8.5	106.1	(48.4-201.5)
Female	2	4.5	nc	(nc-nc)	Female	17	6.9	245.3	(142.8-392.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	9	7.3	123.3	(56.3-234.1)
Female	54	49.9	108.2	(81.3-141.2)	Female	13	6.0	216.2	(115.0-369.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	7	5.4	130.2	(52.2-268.2)
<b><u>Colon / Rectum</u></b>					Female	4	2.4	nc	(nc-nc)
Male	15	16.2	92.6	(51.8-152.7)	<b><u>Ovary</u></b>				
Female	23	15.4	149.4	(94.7-224.2)	Female	6	4.8	125.8	(45.9-273.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	6	4.0	150.8	(55.1-328.3)
Female	2	0.9	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	50	49.5	101.0	(74.9-133.1)
Female	2	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	3.0	166.3	(53.6-388.0)
Male	10	7.0	143.1	(68.5-263.1)	Female	0	1.7	nc	(nc-nc)
Female	5	4.0	126.5	(40.8-295.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	2.1	238.1	(76.7-555.6)
Male	1	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.6	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	9.0	132.9	(68.6-232.1)
Male	4	4.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.4	nc	(nc-nc)	Female	15	11.2	133.5	(74.7-220.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	188	174.1	108.0	(93.1-124.6)
Female	1	1.2	nc	(nc-nc)	Female	206	168.5	122.3	(106.1-140.2)
<b><u>Lung and Bronchus</u></b>									
Male	34	23.1	147.2	(101.9-205.7)					
Female	26	22.7	114.6	(74.9-167.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	2.4	248.3	(90.7-540.5)	Male	3	1.6	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	5	8.2	61.0	(19.7-142.4)	Female	2	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	2.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	9.3	64.7	(23.6-140.8)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	31	32.7	94.7	(64.3-134.5)
Female	0	0.2	nc	(nc-nc)	Female	30	28.0	107.0	(72.2-152.7)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.5	nc	(nc-nc)					
Female	4	3.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	20.1	114.2	(72.3-171.3)	Male	17	12.0	141.2	(82.2-226.1)
Female	7	8.1	86.4	(34.6-178.0)	Female	7	9.5	74.0	(29.6-152.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.5	141.1	(45.5-329.2)	Male	2	3.1	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	13	10.6	123.0	(65.4-210.4)
Female	77	71.2	108.1	(85.3-135.1)	Female	9	9.9	91.2	(41.6-173.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.7	nc	(nc-nc)	Male	6	7.2	82.9	(30.3-180.5)
<b><u>Colon / Rectum</u></b>					Female	2	3.6	nc	(nc-nc)
Male	24	25.0	96.2	(61.6-143.1)	<b><u>Ovary</u></b>				
Female	24	27.5	87.3	(55.9-129.9)	Female	9	7.0	127.9	(58.3-242.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.1	nc	(nc-nc)	Male	2	6.2	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	10	7.3	136.9	(65.5-251.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	96	72.2	133.0	(107.8-162.5)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.8	nc	(nc-nc)
Male	9	9.9	91.3	(41.6-173.3)	Female	3	3.2	nc	(nc-nc)
Female	6	6.1	98.9	(36.1-215.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.0	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	0.8	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	10.3	58.2	(21.3-126.8)
Male	7	6.7	104.1	(41.7-214.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	5.5	nc	(nc-nc)	Female	20	15.7	127.1	(77.6-196.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.1	nc	(nc-nc)	Male	271	258.3	104.9	(92.8-118.2)
Female	0	1.9	nc	(nc-nc)	Female	234	258.9	90.4	(79.2-102.7)
<b><u>Lung and Bronchus</u></b>									
Male	25	36.6	68.3	(44.2-100.8)					
Female	21	38.2	55.0	(34.0-84.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	11.5	174.0	(106.2-268.7)	Male	14	6.2	227.3	(124.2-381.4)
Female	4	3.5	nc	(nc-nc)	Female	6	3.9	154.6	(56.5-336.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.5	nc	(nc-nc)
Female	36	30.3	118.8	(83.2-164.5)	Female	2	4.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.5	nc	(nc-nc)
Male	9	13.5	66.8	(30.5-126.8)	<b><u>Ovary</u></b>				
Female	8	11.0	72.6	(31.3-143.1)	Female	6	3.0	199.8	(73.0-434.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.7	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	51	38.1	133.7	(99.6-175.8)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.6	nc	(nc-nc)
Male	6	5.0	119.7	(43.7-260.5)	Female	1	1.2	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.7	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	4.2	nc	(nc-nc)
Male	7	3.5	199.7	(80.0-411.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.2	nc	(nc-nc)	Female	10	7.0	141.9	(67.9-261.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	150	137.6	109.0	(92.2-127.9)
Female	0	0.8	nc	(nc-nc)	Female	114	109.9	103.7	(85.5-124.6)
<b><u>Lung and Bronchus</u></b>									
Male	12	20.7	58.1	(30.0-101.4)					
Female	15	17.5	85.8	(48.0-141.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	17.9	66.9	(34.5-116.9)	Male	6	11.3	52.9	(19.3-115.1)
Female	5	7.0	71.1	(22.9-166.0)	Female	7	9.4	74.2	(29.7-152.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	6	9.9	60.4	(22.1-131.5)
Female	79	67.6	116.8	(92.5-145.6)	Female	8	8.9	89.8	(38.7-176.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.8	nc	(nc-nc)	Male	11	6.9	159.8	(79.7-285.9)
<b><u>Colon / Rectum</u></b>					Female	3	3.3	nc	(nc-nc)
Male	29	22.9	126.7	(84.8-182.0)	<b><u>Ovary</u></b>				
Female	20	23.9	83.6	(51.1-129.2)	Female	9	6.6	136.0	(62.0-258.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.6	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	4	1.4	nc	(nc-nc)	Female	10	6.3	159.0	(76.1-292.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	82	64.5	127.2	(101.2-157.9)
Female	0	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	4.3	139.4	(50.9-303.3)
Male	11	9.2	120.1	(59.9-214.9)	Female	1	2.7	nc	(nc-nc)
Female	6	5.6	107.0	(39.1-232.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.6	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	14	11.2	124.6	(68.0-209.0)
Male	4	6.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.9	101.4	(32.7-236.7)	Female	9	15.0	59.9	(27.3-113.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.8	nc	(nc-nc)	Male	241	236.2	102.0	(89.6-115.8)
Female	2	1.7	nc	(nc-nc)	Female	238	239.3	99.5	(87.2-112.9)
<b><u>Lung and Bronchus</u></b>									
Male	30	32.4	92.5	(62.4-132.0)					
Female	26	33.9	76.6	(50.0-112.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	18.8	117.1	(73.4-177.3)	Male	20	13.5	148.2	(90.5-228.9)
Female	3	6.7	nc	(nc-nc)	Female	18	11.2	161.3	(95.5-254.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.4	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	6	3.5	172.6	(63.0-375.6)	Female	4	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	12	11.6	103.7	(53.5-181.2)
Female	105	79.1	132.8	(108.6-160.8)	Female	8	9.1	87.8	(37.8-172.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.6	nc	(nc-nc)	Male	5	8.7	57.3	(18.5-133.6)
<b><u>Colon / Rectum</u></b>					Female	5	3.7	136.6	(44.0-318.8)
Male	27	25.5	105.9	(69.8-154.1)	<b><u>Ovary</u></b>				
Female	23	23.0	100.0	(63.4-150.1)	Female	9	7.5	120.1	(54.8-228.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	5.4	128.7	(51.6-265.1)	Male	3	6.2	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	8	5.9	135.3	(58.3-266.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	91	78.4	116.1	(93.4-142.5)
Female	1	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.7	nc	(nc-nc)
Male	8	11.1	72.2	(31.1-142.2)	Female	0	2.5	nc	(nc-nc)
Female	9	6.1	148.1	(67.6-281.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	3.5	169.9	(62.0-369.7)
Male	2	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	5	4.6	109.4	(35.3-255.3)
<b><u>Leukemia</u></b>					Female	20	15.1	132.6	(81.0-204.8)
Male	9	7.2	124.3	(56.7-236.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	5.3	95.1	(30.7-222.0)	Female	21	17.6	119.3	(73.8-182.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	5.8	137.4	(59.2-270.8)	Male	291	274.1	106.2	(94.3-119.1)
Female	1	1.7	nc	(nc-nc)	Female	317	260.9	121.5	(108.5-135.7)
<b><u>Lung and Bronchus</u></b>									
Male	33	35.5	93.1	(64.1-130.7)					
Female	39	33.7	115.8	(82.3-158.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	4.4	135.7	(49.5-295.3)	Male	6	3.0	200.6	(73.3-436.7)
Female	2	1.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	21	16.1	130.6	(80.8-199.7)	Female	3	1.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.8	nc	(nc-nc)
Male	2	5.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	4.9	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	21	18.2	115.1	(71.2-175.9)
Female	2	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.1	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.8	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.1	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	59	62.6	94.2	(71.7-121.5)
Female	0	0.4	nc	(nc-nc)	Female	58	54.2	107.1	(81.3-138.4)
<b><u>Lung and Bronchus</u></b>									
Male	7	8.4	83.5	(33.5-172.1)					
Female	9	7.6	118.4	(54.0-224.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	4	7.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	2.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	8.9	67.2	(24.5-146.3)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	19	31.1	61.0	(36.7-95.3)
Female	0	0.2	nc	(nc-nc)	Female	18	24.4	73.7	(43.7-116.5)
<b><u>Lung and Bronchus</u></b>									
Male	2	4.5	nc	(nc-nc)					
Female	2	3.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	6	6.2	97.3	(35.5-211.7)	Female	1	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.3	nc	(nc-nc)
Male	5	2.5	201.4	(64.9-470.0)	<b><u>Ovary</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	7.2	110.6	(47.6-217.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.0	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.4	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	23	25.7	89.4	(56.6-134.1)
Female	0	0.2	nc	(nc-nc)	Female	23	21.2	108.5	(68.8-162.8)
<b><u>Lung and Bronchus</u></b>									
Male	4	3.5	nc	(nc-nc)					
Female	3	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Essex

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.8	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	12	13.6	88.5	(45.7-154.5)	Female	2	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.6	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.6	nc	(nc-nc)
Male	3	5.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	4.3	138.6	(50.6-301.7)	Female	2	1.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	21	15.1	139.1	(86.1-212.6)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.9	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.3	nc	(nc-nc)
Male	4	1.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.9	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	57	52.8	108.0	(81.8-139.9)
Female	0	0.3	nc	(nc-nc)	Female	49	46.1	106.3	(78.6-140.5)
<b><u>Lung and Bronchus</u></b>									
Male	5	7.2	69.1	(22.3-161.3)					
Female	7	6.4	108.5	(43.5-223.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Everett

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	44	40.0	110.1	(80.0-147.8)	Male	20	24.9	80.4	(49.1-124.3)
Female	11	16.0	68.9	(34.4-123.3)	Female	11	21.0	52.3	(26.1-93.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	7.7	116.6	(53.2-221.4)	Male	5	6.3	79.9	(25.8-186.5)
Female	7	6.7	104.8	(42.0-215.9)	Female	1	5.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	25	21.8	114.9	(74.4-169.7)
Female	128	149.7	85.5	(71.3-101.7)	Female	23	20.1	114.7	(72.7-172.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	6.3	95.6	(34.9-208.1)	Male	14	14.4	97.0	(53.0-162.7)
<b><u>Colon / Rectum</u></b>					Female	5	7.5	67.0	(21.6-156.4)
Male	60	49.7	120.7	(92.1-155.3)	<b><u>Ovary</u></b>				
Female	58	53.3	108.9	(82.7-140.8)	Female	15	14.7	101.8	(56.9-167.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	10.1	118.5	(61.2-207.1)	Male	11	12.4	88.9	(44.3-159.2)
Female	1	3.1	nc	(nc-nc)	Female	14	14.2	98.7	(53.9-165.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	3.7	135.5	(43.7-316.3)	Male	99	142.8	69.3	(56.4-84.4)
Female	1	2.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	9.5	157.9	(88.3-260.5)
Male	19	19.9	95.7	(57.6-149.4)	Female	14	6.0	231.7	(126.6-388.8)
Female	11	12.7	86.8	(43.3-155.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	6.1	nc	(nc-nc)
Male	5	5.8	86.5	(27.9-201.8)	<b><u>Thyroid</u></b>				
Female	6	1.7	347.1	(126.8-755.6)	Male	7	7.5	93.5	(37.5-192.7)
<b><u>Leukemia</u></b>					Female	23	25.1	91.7	(58.1-137.7)
Male	11	13.9	78.9	(39.3-141.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	11.3	88.8	(42.5-163.4)	Female	28	33.5	83.6	(55.5-120.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	10.0	140.2	(76.6-235.2)	Male	481	520.8	92.4	(84.3-101.0)
Female	6	3.9	155.5	(56.8-338.4)	Female	525	536.3	97.9	(89.7-106.6)
<b><u>Lung and Bronchus</u></b>									
Male	69	72.7	95.0	(73.9-120.2)					
Female	105	77.7	135.2	(110.5-163.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	22.6	119.6	(78.8-174.0)	Male	16	13.3	120.7	(68.9-196.0)
Female	10	9.4	106.1	(50.8-195.1)	Female	12	10.8	111.0	(57.3-193.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.9	nc	(nc-nc)	Male	9	3.5	259.3	(118.3-492.2)
Female	3	3.4	nc	(nc-nc)	Female	5	3.0	164.5	(53.0-383.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	12	11.7	102.5	(52.9-179.0)
Female	76	80.0	95.0	(74.8-118.9)	Female	11	11.4	96.5	(48.1-172.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	10	7.8	128.2	(61.4-235.9)
<b><u>Colon / Rectum</u></b>					Female	5	4.1	122.1	(39.3-284.8)
Male	22	27.7	79.5	(49.8-120.4)	<b><u>Ovary</u></b>				
Female	28	32.3	86.8	(57.7-125.5)	Female	9	8.0	112.3	(51.2-213.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	5.6	89.9	(29.0-209.8)	Male	8	6.9	115.4	(49.7-227.3)
Female	0	1.8	nc	(nc-nc)	Female	6	8.5	70.4	(25.7-153.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	98	77.6	126.3	(102.5-153.9)
Female	1	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	5.3	131.9	(52.8-271.8)
Male	11	10.7	102.8	(51.3-184.0)	Female	3	3.7	nc	(nc-nc)
Female	7	6.9	101.7	(40.7-209.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.3	nc	(nc-nc)
Male	7	3.2	220.5	(88.3-454.4)	<b><u>Thyroid</u></b>				
Female	6	0.9	648.0	(236.6-1410.4)	Male	3	3.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	11.5	87.0	(41.7-160.0)
Male	8	7.5	107.1	(46.1-211.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	6.3	nc	(nc-nc)	Female	16	17.7	90.5	(51.7-147.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	5.4	nc	(nc-nc)	Male	330	283.4	116.5	(104.2-129.7)
Female	3	2.2	nc	(nc-nc)	Female	293	295.8	99.1	(88.0-111.1)
<b><u>Lung and Bronchus</u></b>									
Male	50	40.3	124.1	(92.1-163.6)					
Female	60	43.7	137.4	(104.8-176.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	112	103.1	108.7	(89.5-130.7)	Male	42	62.0	67.8	(48.8-91.6)
Female	42	45.3	92.7	(66.8-125.3)	Female	22	54.8	40.1	(25.1-60.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	21	19.0	110.3	(68.2-168.6)	Male	18	15.9	113.2	(67.1-179.0)
Female	16	17.7	90.3	(51.6-146.6)	Female	13	14.6	89.0	(47.3-152.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	52	54.8	94.9	(70.9-124.4)
Female	294	388.4	75.7	(67.3-84.9)	Female	51	55.6	91.7	(68.3-120.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	24	15.4	155.6	(99.7-231.5)	Male	42	36.0	116.6	(84.0-157.6)
<b><u>Colon / Rectum</u></b>					Female	13	20.0	64.9	(34.5-110.9)
Male	135	127.0	106.3	(89.2-125.9)	<b><u>Ovary</u></b>				
Female	157	153.4	102.4	(87.0-119.7)	Female	44	39.1	112.4	(81.7-150.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	31	25.5	121.4	(82.4-172.3)	Male	34	31.7	107.3	(74.3-149.9)
Female	5	8.8	56.6	(18.3-132.2)	Female	39	40.7	95.7	(68.1-130.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	7	8.8	79.9	(32.0-164.6)	Male	273	356.9	76.5	(67.7-86.1)
Female	3	7.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	35	24.3	143.9	(100.2-200.2)
Male	53	49.6	106.9	(80.1-139.8)	Female	37	17.7	209.5	(147.5-288.7)
Female	36	33.8	106.6	(74.7-147.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	13.6	80.9	(40.3-144.8)
Male	24	14.6	164.7	(105.5-245.1)	<b><u>Thyroid</u></b>				
Female	5	4.5	110.8	(35.7-258.6)	Male	15	17.8	84.3	(47.1-139.0)
<b><u>Leukemia</u></b>					Female	63	60.6	103.9	(79.8-132.9)
Male	27	35.6	75.9	(50.0-110.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	42	31.4	133.7	(96.3-180.7)	Female	82	86.3	95.0	(75.6-118.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	32	25.1	127.4	(87.1-179.8)	Male	1350	1313.1	102.8	(97.4-108.4)
Female	8	10.9	73.7	(31.7-145.2)	Female	1301	1444.0	90.1	(85.3-95.1)
<b><u>Lung and Bronchus</u></b>									
Male	269	184.7	145.7	(128.8-164.2)					
Female	187	212.9	87.9	(75.7-101.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	69	57.0	121.0	(94.1-153.1)	Male	34	31.9	106.6	(73.8-148.9)
Female	16	20.6	77.8	(44.4-126.4)	Female	22	23.3	94.3	(59.1-142.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	8.9	89.6	(38.6-176.6)	Male	9	8.6	104.3	(47.6-198.1)
Female	12	7.4	161.7	(83.4-282.4)	Female	8	6.6	120.4	(51.9-237.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	39	28.2	138.5	(98.5-189.3)
Female	203	178.8	113.5	(98.5-130.3)	Female	21	24.8	84.5	(52.3-129.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	6.4	78.5	(25.3-183.1)	Male	21	18.5	113.8	(70.4-174.0)
<b><u>Colon / Rectum</u></b>					Female	12	9.1	131.9	(68.1-230.5)
Male	66	68.5	96.4	(74.5-122.6)	<b><u>Ovary</u></b>				
Female	49	67.7	72.4	(53.5-95.7)	Female	22	17.8	123.4	(77.3-186.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	13.8	72.4	(34.6-133.1)	Male	16	17.3	92.3	(52.7-149.9)
Female	6	4.0	148.9	(54.4-324.0)	Female	18	18.3	98.2	(58.2-155.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	3.3	nc	(nc-nc)	Male	212	195.6	108.4	(94.3-124.0)
Female	4	2.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	13.2	83.2	(41.5-148.8)
Male	33	25.9	127.5	(87.7-179.0)	Female	6	7.7	77.7	(28.4-169.1)
Female	15	15.6	96.2	(53.8-158.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	4.3	115.5	(37.2-269.6)
Male	8	7.9	101.7	(43.8-200.4)	<b><u>Thyroid</u></b>				
Female	1	2.2	nc	(nc-nc)	Male	9	8.1	110.6	(50.5-210.0)
<b><u>Leukemia</u></b>					Female	18	25.0	72.0	(42.7-113.9)
Male	24	18.0	133.1	(85.3-198.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	16	13.4	119.4	(68.2-193.9)	Female	45	41.0	109.7	(80.0-146.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	13.2	68.3	(31.1-129.6)	Male	720	701.4	102.7	(95.3-110.4)
Female	3	4.8	nc	(nc-nc)	Female	668	651.8	102.5	(94.9-110.6)
<b><u>Lung and Bronchus</u></b>									
Male	91	102.5	88.8	(71.5-109.0)					
Female	105	99.9	105.1	(86.0-127.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	39.8	85.5	(59.2-119.5)	Male	13	24.9	52.1	(27.7-89.1)
Female	14	16.5	84.8	(46.3-142.3)	Female	14	21.4	65.5	(35.8-109.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	7.9	75.6	(27.6-164.6)	Male	7	6.3	111.7	(44.8-230.3)
Female	4	7.0	nc	(nc-nc)	Female	7	5.3	131.1	(52.5-270.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	28	22.0	127.5	(84.7-184.2)
Female	128	149.5	85.6	(71.4-101.8)	Female	27	20.6	130.9	(86.3-190.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	6.2	80.7	(26.0-188.3)	Male	18	14.7	122.3	(72.4-193.2)
<b><u>Colon / Rectum</u></b>					Female	5	7.6	65.8	(21.2-153.5)
Male	31	49.9	62.2	(42.2-88.2)	<b><u>Ovary</u></b>				
Female	47	56.1	83.8	(61.5-111.4)	Female	10	14.9	67.0	(32.1-123.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	10.1	98.7	(47.3-181.5)	Male	14	12.4	113.3	(61.9-190.1)
Female	4	3.2	nc	(nc-nc)	Female	10	14.8	67.4	(32.2-123.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.9	nc	(nc-nc)	Male	110	142.2	77.4	(63.6-93.3)
Female	4	3.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	9.5	63.3	(23.1-137.7)
Male	21	20.0	105.1	(65.0-160.6)	Female	6	6.5	92.9	(33.9-202.3)
Female	13	12.7	102.5	(54.5-175.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	6.1	98.0	(35.8-213.3)
Male	6	5.8	103.8	(37.9-225.9)	<b><u>Thyroid</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	2	7.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	24.9	44.2	(22.1-79.2)
Male	12	14.3	84.2	(43.4-147.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	11.9	92.3	(46.0-165.1)	Female	42	33.0	127.2	(91.7-172.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	10.2	78.6	(33.8-154.9)	Male	435	521.6	83.4	(75.7-91.6)
Female	2	4.0	nc	(nc-nc)	Female	484	545.2	88.8	(81.0-97.1)
<b><u>Lung and Bronchus</u></b>									
Male	67	72.1	92.9	(72.0-118.0)					
Female	71	78.1	90.9	(71.0-114.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	3	0.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	11	10.9	100.9	(50.3-180.6)
Female	0	0.1	nc	(nc-nc)	Female	9	8.9	101.1	(46.1-191.9)
<b><u>Lung and Bronchus</u></b>									
Male	2	1.5	nc	(nc-nc)					
Female	1	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	16.1	105.8	(61.6-169.3)	Male	11	10.9	101.0	(50.3-180.7)
Female	2	6.0	nc	(nc-nc)	Female	7	8.7	80.5	(32.3-165.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.5	144.4	(46.5-337.0)	Male	2	2.7	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	7	9.4	74.7	(29.9-153.9)
Female	64	64.8	98.8	(76.1-126.2)	Female	8	7.8	102.3	(44.0-201.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.7	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	5	3.1	163.6	(52.7-381.8)
Male	27	21.1	128.2	(84.4-186.5)	<b><u>Ovary</u></b>				
Female	29	20.1	144.6	(96.8-207.6)	Female	11	6.2	178.3	(88.9-319.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.5	110.4	(35.6-257.7)	Male	7	5.2	134.5	(53.9-277.2)
Female	0	1.2	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	63	65.3	96.5	(74.1-123.5)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	3.9	153.2	(56.0-333.6)
Male	11	9.1	121.5	(60.6-217.4)	Female	2	2.2	nc	(nc-nc)
Female	5	5.2	96.3	(31.0-224.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.4	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.7	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	11.1	63.2	(25.3-130.2)
Male	5	5.9	85.0	(27.4-198.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	4.4	181.5	(78.2-357.7)	Female	18	14.7	122.8	(72.7-194.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.7	nc	(nc-nc)	Male	224	226.5	98.9	(86.4-112.7)
Female	0	1.5	nc	(nc-nc)	Female	240	218.6	109.8	(96.3-124.6)
<b><u>Lung and Bronchus</u></b>									
Male	21	30.4	69.1	(42.8-105.6)					
Female	45	30.3	148.4	(108.3-198.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	54	66.7	81.0	(60.8-105.7)	Male	34	43.4	78.3	(54.2-109.4)
Female	22	25.9	84.8	(53.1-128.4)	Female	24	36.2	66.4	(42.5-98.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	15	13.5	110.7	(61.9-182.6)	Male	12	10.8	111.5	(57.6-194.8)
Female	9	11.3	79.4	(36.2-150.6)	Female	10	8.5	117.9	(56.4-216.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	36	37.6	95.7	(67.0-132.4)
Female	285	255.7	111.5	(98.9-125.2)	Female	23	33.1	69.4	(44.0-104.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	11.1	90.2	(43.2-165.9)	Male	15	26.2	57.2	(32.0-94.3)
<b><u>Colon / Rectum</u></b>					Female	20	12.6	159.0	(97.1-245.5)
Male	84	85.5	98.3	(78.4-121.7)	<b><u>Ovary</u></b>				
Female	102	88.4	115.4	(94.1-140.1)	Female	20	25.0	80.0	(48.8-123.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	17	17.6	96.8	(56.3-154.9)	Male	15	21.0	71.4	(39.9-117.8)
Female	7	5.0	139.8	(56.0-288.1)	Female	20	23.2	86.2	(52.6-133.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	6.4	nc	(nc-nc)	Male	254	249.4	101.8	(89.7-115.2)
Female	4	5.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	16.1	93.2	(52.1-153.8)
Male	35	35.0	100.1	(69.7-139.2)	Female	11	10.0	109.6	(54.6-196.1)
Female	17	21.0	81.0	(47.2-129.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	10.8	74.4	(32.0-146.5)
Male	6	10.1	59.4	(21.7-129.4)	<b><u>Thyroid</u></b>				
Female	3	2.9	nc	(nc-nc)	Male	18	13.6	132.3	(78.3-209.0)
<b><u>Leukemia</u></b>					Female	41	44.5	92.2	(66.1-125.0)
Male	24	23.9	100.5	(64.4-149.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	28	18.9	148.4	(98.6-214.5)	Female	58	56.9	101.9	(77.4-131.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	17.9	72.6	(38.6-124.1)	Male	858	898.6	95.5	(89.2-102.1)
Female	6	6.4	93.6	(34.2-203.8)	Female	918	900.0	102.0	(95.5-108.8)
<b><u>Lung and Bronchus</u></b>									
Male	117	122.1	95.8	(79.2-114.8)					
Female	113	125.2	90.3	(74.4-108.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	22.0	154.6	(107.1-216.1)	Male	17	16.2	105.2	(61.3-168.5)
Female	9	8.2	109.5	(50.0-207.9)	Female	14	13.9	101.0	(55.2-169.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	5.6	124.9	(50.0-257.3)	Male	6	3.8	159.7	(58.3-347.7)
Female	2	4.5	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	10	14.0	71.6	(34.3-131.7)
Female	98	97.3	100.7	(81.7-122.7)	Female	17	11.2	151.3	(88.1-242.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.7	nc	(nc-nc)	Male	9	10.2	88.5	(40.4-167.9)
<b><u>Colon / Rectum</u></b>					Female	6	4.4	135.2	(49.4-294.3)
Male	40	29.8	134.1	(95.8-182.6)	<b><u>Ovary</u></b>				
Female	32	28.3	113.0	(77.3-159.5)	Female	14	9.1	154.1	(84.2-258.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	6.3	nc	(nc-nc)	Male	10	7.2	139.0	(66.6-255.7)
Female	2	1.6	nc	(nc-nc)	Female	7	7.3	96.4	(38.6-198.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	138	88.3	156.3	(131.3-184.6)
Female	3	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	5.5	nc	(nc-nc)
Male	13	13.2	98.5	(52.4-168.5)	Female	3	3.1	nc	(nc-nc)
Female	7	7.5	93.1	(37.3-191.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	4.6	107.6	(34.7-251.1)
Male	0	3.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	6	5.7	105.3	(38.4-229.1)
<b><u>Leukemia</u></b>					Female	25	19.1	131.0	(84.8-193.4)
Male	9	9.0	100.6	(45.9-190.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	6.8	102.3	(41.0-210.7)	Female	14	20.9	66.9	(36.5-112.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.7	74.4	(24.0-173.7)	Male	391	320.4	122.0	(110.2-134.8)
Female	1	2.1	nc	(nc-nc)	Female	336	321.8	104.4	(93.5-116.2)
<b><u>Lung and Bronchus</u></b>									
Male	43	41.3	104.2	(75.4-140.3)					
Female	41	41.3	99.2	(71.2-134.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;